Unboosted atazanavir-based therapy maintains control of HIV type-1 replication as effectively as a ritonavir-boosted regimen

Abstract

Background

Triple combination therapy based on a ritonavir (RTV)-boosted protease inhibitor plus two nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) has improved outcomes in HIV type-1 (HIV-1)-infected patients. For patients unable to tolerate these regimens, alternative therapeutic approaches are needed.

Methods

We report a comparative, open-label study in treatment-naive patients who underwent initial induction treatment with a triple combination including RTV-boosted atazanavir (ATV; 300/100 mg once daily). Patients who achieved an HIV-1 viral load <50 copies/ml after the induction period were then randomized in the maintenance phase either to continue on current treatment or to switch to unboosted ATV 400 mg once daily (plus two NRTIs unchanged).

Results

A total of 252 patients entered the induction phase, of whom 172 were eligible for randomization in the maintenance phase (ATV/RTV n=85 and ATV n=87). The unboosted ATV regimen demonstrated non-inferior efficacy to the ATV/RTV regimen with 78% and 75% of patients, respectively, maintaining virological suppression (HIV-1 RNA <50 copies/ml) up to week 48 after randomization (difference estimate 2.9, 95% confidence interval -9.8–15.5). Time to virological failure and change from the end of the induction phase in mean CD4⁺ T-cell counts were also similar between the treatment arms. Although both regimens were well-tolerated, unboosted ATV was associated with fewer adverse events, fewer total bilirubin abnormalities and an improved lipid profile compared with ATV/RTV.

Conclusions

An HIV-1 combined treatment regimen based on unboosted ATV is a feasible treatment option for patients with established virological control who are unable to tolerate triple combination therapy including ATV/RTV.

References

Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. US Department of Health and Human Services. (Updated 3 November 2008. Accessed September 2009.) Available from http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf.

Hammer

S.M.

, Eron

J.J.

Jr. , Reiss

Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society–USA panel.

JAMA 2008; 300: 555–570.

Reyataz^® (atazanavir sulfate). Package Insert 2009. Bristol–Myers Squibb

Uxbridge, UK.

Reyataz^® (atazanavir sulfate). Highlights of prescribing information. Package Insert 2008. Bristol–Myers Squibb, Uxbridge, UK. (Updated September 2008. Accessed 08 September 2010.) Available from http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021567s017lbl.pdf.

Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report.

Circulation 2002; 106: 3143–3421.

Johnson

M.A.

, Gathe

J.C.

Jr. , Podzamczer

A once-daily lopinavir/ritonavir-based regimen provides noninferior antiviral activity compared with a twice-daily regimen.

J Acquir Immune Defic Syndr 2006; 43: 153–160.

Cooper

, Zajdenverg

, Ruxrungtham

, Chavez

R.L.

Efficacy and safety of two doses of tipranavir/ritonavir versus lopinavir/ritonavir-based therapy in antiretroviral-naive patients: results of BI 1182.33. HIV8, 8th International Congress on Drug Therapy in HIV infection. 12–16 November 2006, Glasgow, UK. Abstract 444.

Molina

J.M.

, Andrade-Villanueva

, Echevarria

Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study.

Lancet 2008; 372: 646–655.

Johnson

, Grinsztejn

, Rodriguez

96-Week comparison of once-daily atazanavir/ritonavir and twice-daily lopinavir/ritonavir in patients with multiple virologic failures.

AIDS 2006; 20: 711–718.

10.

Soriano

, Garcia-Gasco

, Vispo

Efficacy and safety of replacing lopinavir with atazanavir in HIV-infected patients with undetectable plasma viraemia: final results of the SLOAT trial.

J Antimicrob Chemother 2008; 61: 200–205.

11.

Mallolas

, Podzamczer

, Milinkovic

Efficacy and safety of switching from boosted lopinavir to boosted atazanavir in patients with virological suppression receiving a LPV/r-containing HAART: the ATAZIP study.

J Acquir Immune Defic Syndr 2009; 51: 29–36.

12.

Gatell

, Salmon-Ceron

, Lazzarin

Efficacy and safety of atazanavir-based highly active antiretroviral therapy in patients with virologic suppression switched from a stable, boosted or unboosted protease inhibitor treatment regimen: the SWAN Study (AI424-097) 48-week results.

Clin Infect Dis 2007; 44: 1484–1492.

13.

Mobius

, Lubach-Ruitman

, Castro-Frenzel

Switching to atazanavir improves metabolic disorders in antiretroviral-experienced patients with severe hyperlipidemia.

J Acquir Immune Defic Syndr 2005; 39: 174–180.

14.

Jackson

, Patel

, Lo

, Gazzard

, Moyle

Effects of atazanavir or saquinavir once daily with ritonavir 100mg and tenofovir/emtricitabine as initial therapy for HIV-1 infection on peripheral glucose disposal: a randomized open-label study. 14th Conference on Retroviruses and Opportunistic Infections. 25–28 February 2007, Los Angeles, CA, USA. Abstract 818.

15.

Stanley

T.L.

, Joy

, Hadigan

C.M.

Effects of switching from lopinavir/ritonavir to atazanavir/ritonavir on muscle glucose uptake and visceral fat in HIV-infected patients.

AIDS 2009; 23: 1349–1357.

16.

Malan

D.R.

, Krantz

, David

, Wirtz

, Hammond

, McGrath

Efficacy and safety of atazanavir, with or without ritonavir, as part of once-daily highly active antiretroviral therapy regimens in antiretroviral-naive patients.

J Acquir Immune Defic Syndr 2008; 47: 161–167.

17.

Behrens

G.M.

, Reiss

Abacavir and caridiovascular risk.

Curr Opin Infect Dis 2010; 23: 9–14.

18.

Strategies for Management of Anti-Retroviral Therapy/ INSIGHT and the DAD Study Groups.

Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients.

AIDS 2008; 22: F17–F24.

19.

van Vonderen

M.G.

, van Agtmael

M.A.

, Hassink

E.A.

Zidovudine/lamivudine for HIV-1 infection contributes to limb fat loss.

PLoS ONE 2009; 4: e5647.

20.

Garrido

, Soriano

, de Mendoza

New therapeutic strategies for raltegravir.

J Antimicrob Chemother 2010; 65: 218–223.

21.

Allavena

, Mounoury

, Rodallec

Efficacy and safety of an NRTI-sparing dual regimen of raltegravir and ritonavir-boosted protease inhibitor in a triple antiretroviral class-experienced population.

HIV Clin Trials 2009; 10: 337–340.

22.

Steigbigel

R.T.

, Cooper

D.A.

, Teppler

Long-term efficacy and safety of raltegravir combined with optimized background therapy in treatment-experienced patients with drug-resistant HIV infection: week 96 results of the BENCHMRK 1 and 2 Phase III trials.

Clin Infect Dis 2010; 50: 605–612.

23.

Cameron

D.W.

, da Silva

B.A.

, Arribas

J.R.

A 96-week comparison of lopinavir-ritonavir combination therapy followed by lopinavir-ritonavir monotherapy versus efavirenz combination therapy.

J Infect Dis 2008; 198: 234–240.

24.

Asboe

, Williams

I.G.

, Goodall

R.L.

, Darbyshire

J.H.

, Hooker

M.H.

, Babiker

A.G.

A virological benefit from an induction/maintenance strategy: the Forte trial.

Antivir Ther 2007; 12: 47–54.

25.

Squires

Similar efficacy and tolerability of atazanavir (ATV) compared to ATV/ritonavir (RTV, r), each in combination with abacavir/lamivudine (ABC/3TC), after initial suppression with ABC/3TC + ATV/r in HIV-1 infected patients: 84 week results of the ARIES trial. 5th IAS Conference on HIV Pathogenesis, Treatment and Prevention. 19–22 July 2009, Cape Town, South Africa. Abstract WELBB103.

26.

Gallant

J.E.

, DeJesus

, Arribas

J.R.

Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV.

N Engl J Med 2006; 354: 251–260.

27.

Sax

, Tierney

, Collier

ACTG 5202: shorter time to virologic failure (VF) with abacavir/lamivudine (ABC/3TC) than tenofovir/emtricitabine (TDF/FTC) as part of combination therapy in treatment-naive subjects with screening HIV RNA ≥100,000 c/ml. 17th International AIDS Conference. 3–8 August 2008, Mexico City, Mexico. Abstract THAB0303.

28.

Valantin

M.A.

, de Truchis

, Bittar

Switching NRTI backbone to tenofovir plus emtricitabine (Truvada) promptly improves triglycerides and LDL-cholesterol levels in dyslipidemic HIV patients: the TOTEM randomised trial. 17th International AIDS Conference. 3–8 August 2008, Mexico City, Mexico. Abstract THPE0156.

29.

Soriano

, Köppe

, Mingrone

Prospective comparison of nevirapine and atazanavir/ritonavir both combined with tenofovir DF/emtricitabine in treatment-naive HIV-1 infected patients: ARTEN study week 48 results. 5th IAS Conference on HIV Pathogenesis, Treatment and Prevention. 19–22 July 2009, Cape Town, South Africa. Abstract LBPE07.

30.

Electronic Medicines Compendium. Reyataz^® 150 mg, 200 mg and 300 mg hard capsules. (Updated 12 August 2010. Accessed 8 September 2010.) Available from http://www.medicines.org.uk/emc/medicine/14145/.